Skip to main content

Johnson & Johnson news and events in 2026

Johnson & Johnson is a multinational corporation that develops pharmaceutical treatments and medical technology. The organization focuses on biotechnology and the creation of medical devices to treat and prevent complex diseases.

Public (JNJ)Pharmaceutical Manufacturing10,000+ employeesjnj.comLinkedIn

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.
Dated updates
88
Last event
Nov 17, 2026
Open rolesSnapshot Nov 17, 2026
693
Latest SEC filing
Oct 21, 2026

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Overview

Johnson & Johnson by topic

Latest events

Latest Johnson & Johnson events

  1. Partnership
  2. Funding
    J&J Secures $750 Million in Blackstone R&D Funding, Pending Ollin ClosingJohnson & Johnson secured $750 million in R&D funding from Blackstone Life Sciences for Phase 3 development of OLN324, contingent on closing its Ollin acquisition.
  3. Acquisition
    Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.3 BillionJohnson & Johnson has agreed to acquire Ollin Biosciences for $2.2 billion upfront and up to approximately $1.1 billion in milestone payments.
  4. Investment
  5. Integration
  6. In development
    Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancerJohnson & Johnson is developing an investigational dual-antigen immunotherapy combination of pasritamig and JNJ-9401 for the treatment of advanced prostate cancer, with the regimen entering Phase 3 development.
  7. In development
    Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily...Johnson & Johnson announced positive Phase 3 results for its investigational targeted oral peptide ICOTYDE (icotrokinra) in treating biologic-naive adults with active psoriatic arthritis.
  8. In development
    RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancerJohnson & Johnson released results from the Phase 1b/2 OrigAMI-4 study and expanded the clinical development of subcutaneous RYBREVANT (amivantamab) for head and neck cancer.
  9. In development
    RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerJohnson & Johnson is developing subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) in ongoing Phase 1b/2 and Phase 3 clinical studies for advanced head and neck cancer.
  10. In development
    Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerJohnson & Johnson announced Phase 3 PROTEUS substudy results evaluating the investigational use of ERLEADA (apalutamide) plus androgen deprivation therapy before and after surgery in high-risk prostate cancer.

Showing 10 of 31 events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Johnson & Johnson with the Signal API

One POST /v1/companies/enrich call with jnj.com returns every signal type for Johnson & Johnson, each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Same industry

Johnson & Johnson questions

What is the latest news on Johnson & Johnson?
On Nov 16, 2026, boursorama.com reported: J&J to acquire eye disease-focused biotech firm Ollin Biosciences for up to. This page tracks 31 news events for Johnson & Johnson since Aug 1, 2026, each with a date and a source link.
What is going on with Johnson & Johnson?
In the 90 days to Nov 19, 2026, Autobound tracked 30 news events, 1 10-Q filing, 1 8-K filing, 4 hiring snapshots, 1 funding event, 1 reported layoff round, 1 deal, 34 signals for Johnson & Johnson. The newest story is from Nov 16, 2026 (Partnership), reported by boursorama.com.
Is Johnson & Johnson laying off employees?
ad-hoc-news.de reported on Sep 21, 2026: Johnson & Johnson Stock Reacts to New Earnings Estimates and Job Cut Signal. Autobound lists 1 reported layoff round for Johnson & Johnson. Each row states what its source reported, not a confirmed total.
Has Johnson & Johnson announced any acquisitions?
The latest deal story is from Nov 16, 2026. citybiz.co reported: Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.3 Billion. The acquisitions page lists 1 deal with a source for each.
What else does Autobound track for Johnson & Johnson?
Beyond news and filings, Autobound lists 50+ signals for Johnson & Johnson from 6 sources: Glassdoor (15+), Patents (12), LinkedIn (11), Reddit (5), Podcasts (4), Web traffic (3). See the Johnson & Johnson signals page for the dated list.
Is Johnson & Johnson hiring right now?
Yes. As of Nov 17, 2026, Johnson & Johnson had 693 open roles, and Sales had the most with 119.

Page updated , the date of the newest row on this page.

Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.

Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.

Data as of .

How this data is built →Get it from the Signal API →